Landscapes / Targets
HER2
77 drugs act on HER2, in 235 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs77
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Hengrui · Public 600276.SS |
Approved in China | Nov 2026soonPhase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Ovarian Cancer, Advanced Colorectal Cancer and 14 more | ||||
| Open drug page | |||||
HER2 inhibitor |
Boehringer Ingelheim · Private |
Approved | 10 Dec 2026soonPhase 3 trial completes | ||
| Next date | 10 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Lung Cancer, Non-squamous, Non-small Cell and 7 more | ||||
| Open drug page | |||||
Bispecific HER2-directed antibody |
Approved | 31 Dec 2026Phase 2 trial completes | |||
| How it works | Blocks HER2 | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Gastric Neoplasms and 14 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 31 Dec 2026Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion and 2 more | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Approved | 31 Jan 2027Phase 1 trial completes | ||
| Next date | 31 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Breast Cancer, Breast Neoplasms and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Daiichi Sankyo +1 · Public AZN |
Approved | 10 Feb 2027Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 10 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Non-Small Cell Lung Cancer and 34 more | ||||
| Open drug page | |||||
HER2/neu receptor antagonist |
Roche · Public ROG.SW |
Approved | 28 Mar 2027Phase 3 trial completes | ||
| How it works | Blocks HER2 | ||||
| Next date | 28 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Neoplasm Metastasis, Solid Tumors and 3 more | ||||
| Open drug page | |||||
HER2/neu receptor antagonist |
Roche · Public ROG.SW |
Approved | 28 Mar 2027Phase 3 trial completes | ||
| How it works | Blocks HER2 | ||||
| Next date | 28 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Breast Cancer and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Roche · Public ROG.SW |
Approved | 31 Mar 2027Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 31 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Neoplasm Metastasis, Solid Tumors and 2 more | ||||
| Open drug page | |||||
— |
Roche · Public ROG.SW |
Approved | 3 May 2027Phase 3 trial completes | ||
| Next date | 3 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Locally Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer | ||||
| Open drug page | |||||
HER2/EGFR inhibitor |
Approved | 28 Oct 2027Phase 3 trial completes | |||
| Next date | 28 Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Advanced Non-small Cell Lung Cancer, EGFR Mutation and 1 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Pfizer · Public PFE |
Approved | 31 Dec 2027Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Biliary Tract Neoplasms, Breast Neoplasms and 24 more | ||||
| Open drug page | |||||
— |
Shanghai JMT-Bio +1 |
Phase 3 | 16 Dec 2026soonPhase 3 trial completes | ||
| Next date | 16 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Stomach Cancer | ||||
| Open drug page | |||||
— |
Alphamab +1 |
Phase 3 | 30 Dec 2026Phase 3 trial completes | ||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Breast Cancer and 3 more | ||||
| Open drug page | |||||
HER2-targeted antibody-drug conjugate |
Phase 3 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer, Biliary Tract Cancer and 32 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Malignant Tumors, Non Small Cell Lung Cancer (NSCLC) and 2 more | ||||
| Open drug page | |||||
Pyrotinibnot checked |
Tyrosine kinase inhibitor |
Hengrui · Public 600276.SS |
Phase 3 | 31 Dec 2026Phase 3 trial completes | |
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Metastatic Breast Cancer, Recurrent Breast Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | 9 Jan 2027Phase 3 trial completes | |||
| Next date | 9 Jan 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | Jan 2027Phase 3 trial completes | |||
| Next date | Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer, Advanced Cancer and 6 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 74 of 77 drugs. The other 3 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026